Skip to content

A clinical study for evaluating the effects of lactic acid bacteria FK-23 on controlling intestinal functions (improvement of bowel movement)

A clinical study for evaluating the effects of lactic acid bacteria FK-23 on controlling intestinal functions (improvement of bowel movement) - A clinical study for evaluating the effects of lactic acid bacteria FK-23 on controlling intestinal functions (improvement of bowel movement)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000021097
Enrollment
60
Registered
2016-05-31
Start date
2016-02-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Powder food containing FK-23 (0.25 g) Powder food containing FK-23 (0.075 g) Powder food containing FK-23 (0.025 g) Powder food not containing FK-23 (placebo)

Sponsors

Soiken Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Healthy subject within 20-65 years of age, both genders, with constipation tendency (with defecation frequency from 3 to 5 times per week) 2)Subject having a briefing of the content of the present study, fully understanding and agreeing to its objective and being able to personally sign a written informed consent

Exclusion criteria

Exclusion criteria: 1)Subject receiving treatment for gastrointestinal diseases 2)Subject having a medical history with organic constipation or irritable bowel syndrome 3)Subject taken medicines for intestinal disorder or laxatives 4)Subject taking medicine, quasi-drugs, food for specified health uses or foods with functional claims having the effects for intestinal functions 5)Subject having serious liver diseases, cardiovascular, respiratory, endocrine or metabolic disorders, or having a medical history with them 6)Subject have a medical history with test food-ralated allergy 7)Female subject who is pregnant or lactating, or intending to become pregnant during the study 8)Subject who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study 9)Subject deemed unsuitable by the investigator

Design outcomes

Primary

MeasureTime frame
Defecation frequency

Secondary

MeasureTime frame
Population of bifidobacterium to total bacteria, feeling after defecation, smell of feces, defecation days, fecal condition

Countries

Japan

Contacts

Public ContactTomohiro Sugino

Soiken Inc. R&D Division

sugino@soiken.com06-6871-8888

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026